These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 38112999)

  • 21. N
    Dong S; Wu Y; Liu Y; Weng H; Huang H
    Cancer Commun (Lond); 2021 Jul; 41(7):538-559. PubMed ID: 33955720
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor neoantigens: from basic research to clinical applications.
    Jiang T; Shi T; Zhang H; Hu J; Song Y; Wei J; Ren S; Zhou C
    J Hematol Oncol; 2019 Sep; 12(1):93. PubMed ID: 31492199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Roles and implications of mRNA N
    Zeng L; Huang X; Zhang J; Lin D; Zheng J
    Cancer Commun (Lond); 2023 Jul; 43(7):729-748. PubMed ID: 37350762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
    Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
    J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. N
    Dong L; Cao Y; Hou Y; Liu G
    J Cell Physiol; 2022 Jan; 237(1):329-345. PubMed ID: 34515345
    [TBL] [Abstract][Full Text] [Related]  

  • 26. m
    Peng C; Xiong F; Pu X; Hu Z; Yang Y; Qiao X; Jiang Y; Han M; Wang D; Li X
    Front Immunol; 2023; 14():1326031. PubMed ID: 38187373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer immunotherapies: advances and bottlenecks.
    Rui R; Zhou L; He S
    Front Immunol; 2023; 14():1212476. PubMed ID: 37691932
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape.
    Mittal D; Gubin MM; Schreiber RD; Smyth MJ
    Curr Opin Immunol; 2014 Apr; 27():16-25. PubMed ID: 24531241
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune Therapy Resistance and Immune Escape of Tumors.
    Seliger B; Massa C
    Cancers (Basel); 2021 Feb; 13(3):. PubMed ID: 33535559
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acquired resistance during adoptive cell therapy by transcriptional silencing of immunogenic antigens.
    Wylie B; Chee J; Forbes CA; Booth M; Stone SR; Buzzai A; Abad A; Foley B; Cruickshank MN; Waithman J
    Oncoimmunology; 2019; 8(8):1609874. PubMed ID: 31413920
    [TBL] [Abstract][Full Text] [Related]  

  • 31. OMIC signatures to understand cancer immunosurveillance and immunoediting: Melanoma and immune cells interplay in immunotherapy.
    León-Letelier RA; Bonifaz LC; Fuentes-Pananá EM
    J Leukoc Biol; 2019 May; 105(5):915-933. PubMed ID: 30698862
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular Immunotherapy: Promising Approach to Treat Metastatic Colorectal Cancer by Targeting Resistant Cancer Cells or Cancer Stem Cells.
    Forster S; Radpour R
    Front Oncol; 2020; 10():569017. PubMed ID: 33240813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lysine methylation modifications in tumor immunomodulation and immunotherapy: regulatory mechanisms and perspectives.
    Luo Y; Lu J; Lei Z; Zhu H; Rao D; Wang T; Fu C; Zhang Z; Xia L; Huang W
    Biomark Res; 2024 Jul; 12(1):74. PubMed ID: 39080807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression.
    Saleh R; Toor SM; Sasidharan Nair V; Elkord E
    Front Immunol; 2020; 11():1469. PubMed ID: 32760400
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The potential role of m6A modifications on immune cells and immunotherapy.
    Gan L; Zhao Y; Fu Y; Chen Q
    Biomed Pharmacother; 2023 Apr; 160():114343. PubMed ID: 36758318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. N6-methyladenosine (m6A) in cancer therapeutic resistance: Potential mechanisms and clinical implications.
    Wang D; Zhang Y; Li Q; Zhang A; Xu J; Li Y; Li W; Tang L; Yang F; Meng J
    Biomed Pharmacother; 2023 Nov; 167():115477. PubMed ID: 37696088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. m
    Huang H; Weng H; Chen J
    Cancer Cell; 2020 Mar; 37(3):270-288. PubMed ID: 32183948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Innate Immune Cells and Their Contribution to T-Cell-Based Immunotherapy.
    Ginefra P; Lorusso G; Vannini N
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32580431
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Interplay between T Cells and Cancer: The Basis of Immunotherapy.
    Chen C; Liu X; Chang CY; Wang HY; Wang RF
    Genes (Basel); 2023 Apr; 14(5):. PubMed ID: 37239368
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biological and pharmacological roles of m
    Liu Z; Zou H; Dang Q; Xu H; Liu L; Zhang Y; Lv J; Li H; Zhou Z; Han X
    Mol Cancer; 2022 Dec; 21(1):220. PubMed ID: 36517820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.